Clinical Trial Update: A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant study to evaluate Zanidatamab in combination with chemotherapy for HER2-positive breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Zanidatamab

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: HER2-positive Breast Cancer, Breast Cancer | Phase 2 | Status: RECRUITING